Message From
The CEO

The year 2021 marked the tenth anniversary of WuXi Biologics. We have long integrated environmental, social, and governance (ESG) criteria into our daily business activities. Now we have an ESG committee and a dedicated function, all tasked with optimizing our ESG management and performance. We have upgraded our ESG strategy by aligning with the United Nations’ Sustainable Development Goals (SDGs), and we have established effective and transparent communications with stakeholders — identifying and collaboratively pursuing our common goals for over 20 important ESG issues. An evaluation system constantly monitors our ESG performance to ensure that we honor our commitments.

In 2021, we were recognized as an ESG Industry Top-Rated Company by Sustainalytics, were cited for ‘Best ESG’ by Institutional Investor, and earned the Excellence in Corporate Governance Award from the Chamber of Hong Kong Listed Companies .

Over the past decade, WuXi Biologics is proud to have grown into a leading global Contract Research, Development, and Manufacturing Organization (CRDMO). Our advanced, integrated biologics platform provides clients with end-to-end services — enabling them to discover, develop, and manufacture biologics, and accelerating their efforts to bring lifesaving drugs to patients around the world.

Since the pandemic outbreak in 2020, our leading technologies, best-in-class quality, and sound operational support have enabled close to 30 Investigational New Drug Applications (INDs) for COVID-19 drugs and vaccines. By the end of 2021, we had delivered more than 1,500 kg of neutralizing antibodies and hundreds of millions of vaccine doses. It was our robust business continuity management and multiple sourcing strategies throughout the pandemic that allowed us to make these significant contributions to global public health.

Innovation is our driving force. Over the past decade, WuXi Biologics has developed multiple novel technology platforms. These cover the entire spectrum of biologics development from concept to commercial manufacturing. Our large and diverse portfolio includes monoclonal antibodies, bispecific antibodies, multi-specific antibodies, antibody drug conjugates (ADCs), fusion proteins, and vaccines. We were named winner of the APAC Bioprocessing Excellence by the market intelligence company IMAPAC. By the end of 2021, we had manufactured more than 1,700 batches of drug substance, at an outstanding 98% success rate.

Quality is a hallmark of WuXi Biologics. Evidence to our unwavering commitment to quality is demonstrated by passing 22 inspections by global drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Medical Products Administration of China (NMPA) by the end of 2021.

Compliance is a cornerstone of our business. In 2021, all staff undertook compliance training, with a 100% participation and pass rate. We place particular emphasis on information security and business intelligence protection. In 2021, we organized multiple training courses for all personnel categories, optimized our IT security, and completed the ISO 27001 certification.

Operational excellence continues to be our priority. We earn our clients’ trust with our flexibility, speed, innovation, high quality, flawless compliance, intellectual property protection, information security, and adherence to environmental health and safety guidelines. In 2021, WuXi Biologics received Life Science Leader “CMO Leadership Awards” for the fifth year in a row. And we had more than 470 global partners — including the world’s top 20 large pharmaceutical companies.

Innovation is our driving force. Over the past decade, WuXi Biologics has developed multiple novel technology platforms. These cover the entire spectrum of biologics development from concept to commercial manufacturing. Our large and diverse portfolio includes monoclonal antibodies, bispecific antibodies, multi-specific antibodies, antibody drug conjugates (ADCs), fusion proteins, and vaccines. We were named winner of the APAC Bioprocessing Excellence by the market intelligence company IMAPAC. By the end of 2021, we had manufactured more than 1,700 batches of drug substance, at an outstanding 98% success rate.

Quality is a hallmark of WuXi Biologics. Evidence to our unwavering commitment to quality is demonstrated by passing 22 inspections by global drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Medical Products Administration of China (NMPA) by the end of 2021.

Compliance is a cornerstone of our business. In 2021, all staff undertook compliance training, with a 100% participation and pass rate. We place particular emphasis on information security and business intelligence protection. In 2021, we organized multiple training courses for all personnel categories, optimized our IT security, and completed the ISO 27001 certification.

Operational excellence continues to be our priority. We earn our clients’ trust with our flexibility, speed, innovation, high quality, flawless compliance, intellectual property protection, information security, and adherence to environmental health and safety guidelines. In 2021, WuXi Biologics received Life Science Leader “CMO Leadership Awards” for the fifth year in a row. And we had more than 470 global partners — including the world’s top 20 large pharmaceutical companies.

The occupational safety of staff is paramount. In 2021, we conducted more than 100 safety and health training sessions, to enhance our people’s health and safety awareness, and ensure our production and operation activities comply with laws and regulations.

We are committed to building a sustainable supply chain and applying our high standards of business ethics to suppliers. Guidelines for suppliers include our values, as well as social and environmental responsibilities, and we will continue to strengthen our guidance and supervision of the supply chain.

Echoing the global call for action on climate change, WuXi Biologics conducted risk identification and analysis in line with the Task Force on Climate-Related Financial Disclosures (TCFD). In 2021, we set a medium-to long-term greenhouse gas (GHG) emissions target to reduce Scope 1 and 2 carbon emissions intensity by 50% from the 2020 level by 2030.

A concrete action plan to increase investment in the management of energy and emissions was established. As part of that plan, we invited an independent and accredited professional agency to conduct a comprehensive GHG emissions audit based on the ISO 14064 standard. The results showed an 8% year-on-year decrease in GHG emissions intensity. And thanks to our large-scale adoption of environmentally friendly single-use technology, we saved approximately 70% of water and 30% of energy compared to traditional stainless-steel manufacturing technologies and operations. Our water consumption intensity decreased by 13% year on year, and our energy efficiency has improved for three consecutive years.

WuXi Biologics is committed to providing equal opportunities to all employees and to fostering a culture of diversity, equity, and inclusion (DEI). Of our 10,000+ employees, more than 53% are women, and we honor their significant contributions to the fields of science, technology, engineering, and mathematics (STEM). The Women in STEM Committee at our Ireland site reflects our ongoing effort to the professional development of our female colleagues.

WuXi Biologics has over 650 PhDs and one of the world’s largest biologics R&D teams, comprising 3,285 R&D professionals. In 2021, we launched a Global Partner Program to attract and retain exceptional talent.

Since its founding, WuXi Biologics has consistently practiced social responsibility and encouraged staff to give back to communities. In 2021, staff from four countries and nine cities contributed a total of 3,192 hours to volunteer initiatives, covering public health, environmental protection, and youth education. In July 2021, in the wake of the Henan flood disaster, WuXi Biologics and its Charity Foundation immediately donated RMB 10 million for disaster relief and provided financial support for impacted staff.

Going forward, as a global leading CRDMO company, WuXi Biologics will continue to refine its corporate governance, drive innovation, enhance green operations, and actively fulfill its social responsibilities. And, acting on the United Nations SDGs, we will make unstinting efforts to improve human health and well-being.

On behalf of WuXi Biologics, I give thanks to our global clients for their trust, to our investors for their recognition, to our business partners for their support and, of course, to all WuXi Biologics associates for their dedication and contributions.

Dr. Chris Chen
Chief Executive Officer